Evidence map›Paper›PMID 30923097›Full record

Trial reportHaematologica2019

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.

Anthony R Mato, William G Wierda, Matthew S Davids, Bruce D Cheson, Steven E Coutre, Michael Choi, Richard R Furman, Leonard Heffner, Paul M Barr, Herbert Eradat and 6 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. 2-[Medicina (Kaunas, Lithuania) · 2024
    Article
  8. Review
  9. Richter's Transformation.Current oncology reports · 2022
    Review
  10. Article
  11. Approaches for relapsed CLL after chemotherapy-free frontline regimens.Hematology. American Society of Hematology. Education Program · 2020
    Review
  12. Review
  13. Article
  14. [Hybrid imaging in lymphoma].Der Radiologe · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 1 country.

Anthony R MatoCLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY matoa@mskcc.org.
William G WierdaUniversity of Texas MD Anderson Cancer Center, Houston, TX.
Matthew S DavidsDana-Farber Cancer Institute, Boston, MA.
Bruce D ChesonGeorgetown University Hospital, Washington, DC.
Steven E CoutreStanford Cancer Center, Stanford University School of Medicine, Stanford, CA.
Michael ChoiUCSD Moores Cancer Center, San Diego, CA.
Richard R FurmanWeill Cornell Medicine, New York, NY.
Leonard HeffnerEmory University School of Medicine, Atlanta, GA.
Paul M BarrWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
Herbert EradatUniversity of California Los Angeles, Los Angeles, CA.
Sharanya M FordAbbVie Inc. North Chicago, IL.
Lang ZhouAbbVie Inc. North Chicago, IL.
Maria VerdugoAbbVie Inc. North Chicago, IL.
Rod A HumerickhouseAbbVie Inc. North Chicago, IL.
Jalaja PotluriAbbVie Inc. North Chicago, IL.
John C ByrdThe Ohio State University, Columbus, OH, USA.
AbbVie (United States) · USCornell University · USDana-Farber Cancer Institute · USEmory University · USGeorgetown University · USMemorial Sloan Kettering Cancer Center · USMoores Cancer CenterStanford University · USThe Ohio State University · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, Los Angeles · USUniversity of Rochester Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

The utility of positron emission tomography-computed tomography (PET-CT) in distinguishing Richter's transformation

Indexed as

Molecular Targeted TherapyPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overBiopsyDisease ProgressionFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedReceptors, Antigen, B-CellSignal TransductionTreatment OutcomeYoung AdultReceptors, Antigen, B-Cell

Identifiers

PMID30923097
PMCPMC6821597
OpenAlexW2934305708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.